26 results about "Protective antibody" patented technology

Provided are a GLP1 analogue and GLP1 / GIP receptor co-agonist analogues, a fusion protein comprising the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, and methods of use thereof. In various embodiments, the fusion protein comprises the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue fused to a protecting antibody or further fused to a stabilizing domain. In some embodiments, the fusion proteins are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides construction of a fusion recombinant protein ABT for preventing brucellosis and application of the fusion recombinant protein ABT in preparation of protective vaccines. The fusion recombinant protein ABT is composed of an immunological enhancement antigen and a multi-epitope tandem antigen, wherein the immunological enhancement antigen (named as A) comprises a Brucella ribosome L7 / L12 protein and a PADRE sequence; the multi-epitope tandem antigen is formed by connecting a dominant B cell epitope part (named as B), a dominant Tc cell epitope part and a dominant Th cell epitope part (named as T) in series, wherein the dominant B cell epitope part (named as B) is derived from Brucella SurA, OMP31, BP26 and Trigger factor proteins. The ABT Brucella multi-epitope subunit vaccine prepared by mixing the fusion recombinant protein ABT and an immunologic adjuvant has the characteristics of good purity, high safety and strong immunogenicity, can stimulate an organism to generate a protective antibody, and has long antibody maintenance time.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

The invention discloses an influenza A virus Vero cell cold adapted strain Vca-CPD and application thereof, and relates to the field of biotechnology and vaccinology. The preservation number of the Vca-CPD provided by the invention is CCTCC (China Center For Type Culture Collection) NO: V202585. The strain is mainly obtained by performing codon pair optimization on PB2, PA and NP genes. In-vivo and in-vitro experiments prove that the replication ability of the strain in human cells and mammal models is obviously weakened, and the safety is improved; meanwhile, an organism can be induced to generate high-level and specific serum protective antibodies and respiratory mucosa sIgA antibodies. In addition, the virus yield of the strain in production of stromal cells is equivalent to that of a parent strain, and the strain shows good production applicability.

This invention discloses a multi-epitope virus-like particle antigen (VLP) of type O foot-and-mouth disease virus (FMDV), its preparation method, and its application. The type O FMDV VLP antigen is a recombinant antigen protein formed by sequentially tandemly connecting the antigenic epitopes of five representative strains of type O FMDV topotypes—O / Tibet / CHA / 99, O / Mya98 / BY / 2010, O / HN / CHA / 93, O / XJPS / CHA / 2017, and Cathay—with the SpyCather and bacteriophage AP205 genes, and then tandemly connecting them with the epitopes of the first four strains. This recombinant protein can self-assemble into a VLP antigen. Immunological experiments show that this VLP antigen has good antigenicity, and its antigenic reactivity with type O FMDV is not significantly different, making it a viable alternative to inactivated FMDV antigens in detection methods. Vaccines prepared using this VLP antigen not only induce high levels of protective antibodies but also protect immunized animals against viral challenge. Furthermore, it is not limited by animal species and provides immune protection against type O foot-and-mouth disease in pigs, cattle, and sheep.

The application provides a Marburg GP protein mutant, a DNA molecule, a recombinant vector and application thereof, and belongs to the technical field of Marburg virus vaccine preparation. The Marburg GP protein mutant is obtained by site mutation on the basis of a wild-type Marburg GP protein, and contains at least one mutation selected from R575P, V576P and L585P. The amino acid sequence of the wild-type Marburg GP protein is shown as SEQ ID NO:1. The Marburg GP mutant can provide a stable GP pre-fusion conformation, and can induce stronger binding activity, neutralizing activity and protective antibodies in mice, and is expected to be used for preparation of a Marburg virus vaccine.

The present invention discloses a genetically attenuated marker vaccine strain rMG7-L-V1291I of Newcastle disease virus genotype VII, with a preservation number of CGMCC No. 46291. The complete gene nucleotide sequence of this vaccine strain is shown as SEQ ID No: 1; among them, the 1291st amino acid valine (V) of the L protein is replaced by isoleucine (I). The present invention utilizes a reverse genetics operation platform for Newcastle disease virus, based on the Newcastle disease virus MG7 strain, mutates different sites, and rescues a genetically attenuated marker vaccine strain rMG7-L-V1291I of Newcastle disease virus genotype VII with low pathogenicity, good growth characteristics, high virus titer, stable passage ability, and excellent immunogenicity. This marker vaccine strain has good immunogenicity, can induce high levels of protective antibodies, achieve complete protection for immunized chickens, can be used for the prevention and control of currently prevalent Newcastle disease virus genotype VII, and lay a foundation for differentiating vaccine immunization and wild virus infection.

The application belongs to the technical field of biology and specifically relates to a porcine epidemic diarrhea virus (PEDV) recombinant strain with enhanced virulence and construction and application thereof. The amino acid sequence NHTA of the N-connection glycosylation modification site at the 1196th position of the PEDV S protein is mutated into THTA, and a recombinant strain rPEDV-S is obtained by rescue N1196T ; compared with rPEDV-S wt , the virulence of the recombinant strain rPEDV-S N1196T is significantly enhanced, which can be used as an infection strain for evaluating the efficiency of a vaccine; the recombinant strain rPEDV-S wt can induce protective antibodies and can effectively resist the infection of rPEDV-S, and can be used for preparing a PEDV vaccine and is also suitable for reverse design of a new attenuated live vaccine.

The invention relates to the technical field of biology, in particular to a chicken-derived riemerella anatipestifer disease trivalent inactivated vaccine. The inactivated vaccine contains a chicken source riemerella anatipestifer inactivated antigen and an SEPPIC water adjuvant MONTANIDE GEL 02 PR, wherein the chicken source riemerella anatipestifer inactivated antigen is prepared from the chicken source riemerella anatipestifer; the inactivated antigen is a serum type 1 chicken source riemerella anatipestifer DHN-2025-RA-CK018 strain, a serum type 5 chicken source riemerella anatipestifer DHN-2025-RA-CK006 strain and a serum type 10 chicken source riemerella anatipestifer DHN-2025-RA-CK033 strain, the inactivated antigen is preserved in Guangdong Province Microbial Culture Collection Center in August 28, 2025, and the preservation numbers of the inactivated antigen are GDMCC NO: 66885, GDMCC NO: 66884 and GDMCC NO: 66886 respectively. The vaccine can effectively induce a high-titer protective antibody and resist corresponding serotype infection. In addition, the safety of the vaccine is effectively improved by adopting a novel polymer water adjuvant of French Saccharomyces cerevisiae MONTANIDE GEL 02 PR. Meanwhile, the invention also discloses a preparation method of the vaccine.

This invention discloses a combination of *Haemaphysema contortus* antigen proteins and its application in the preparation of a protective subunit vaccine against *Haemaphysema contortus*, belonging to the field of veterinary vaccines. The subunit vaccine of this invention comprises galactose and fucose-modified antigen proteins MEP1, MEP3, MEP4, PEP2, and CP1. The fucose modification includes proximal and distal α1,3-fucose modification. The antigen proteins in this subunit vaccine are closer to the natural proteins in terms of N-glycosylation modification, and can induce protective antibodies in goats after mixed immunization, significantly reducing the number of *Haemaphysema contortus* parasites and the number of eggs laid by the parasites. The subunit vaccine of this invention can be used to prepare drugs for the prevention and treatment of *Haemaphysema contortus* disease. This invention lays the foundation for the development of *Haemaphysema contortus* subunit vaccines, provides an effective technical means for the prevention and treatment of this disease, and has significant application value and promising prospects for promotion.

Developing an effective HIV-1 vaccine is contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, the inventors aimed to refine Langerhans cells (EC) targeting by designing three Env monochains instead of 2 (EC3. Env3) mimicking natural Env conformation. The inventors demonstrated that EC3. Env3 construct (i) elicited a rapid and potent Env-IgG response, (ii) enhanced the avidity of anti-Env IgG that was accompanied by a marked expansion of Tfh and GC B cells and (iii) swiftly induced the formation of structured germinal centers in dLN, indicative of a robust immune response. Finally, significant Tier-1 NeutAb induction was observed in rabbits immunized with the construct. In conclusion, HIV Env antigen can be adaptively targeted to LC as a timer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such a construct as LC targeting HIV-1 vaccines.

The application relates to the technical field of antibodies, in particular to a novel coronavirus Omicron mutant specific antibody and application thereof. The application provides an antibody specifically combined with the novel coronavirus Omicron mutant, the antibody can be used as a specific antibody for antigen detection of the Omicron mutant, is used for identification of a novel coronavirus vaccine designed for the Omicron mutant, and is used for quantitative detection of the content of Spike RBD protein expressed by the vaccine, or is used for quality control of a novel coronavirus vaccine and immunogenicity detection of clinical and preclinical research, or is used as a quality control antibody for detection of protective antibodies in serum after vaccination.

The application specifically relates to a 24-gene-deleted attenuated African swine fever virus strain and application as a vaccine. In the ASFV-CN / GS-2018 virus, 24 genes, including KP177R, L83L, L60L, ASFV-G-ACD-00090, ASFV-G-ACD-00120, 285L, ASFV-G-ACD-00160, and MGF-360, MGF-110, MGF-300, MGF-100, are jointly deleted to obtain an attenuated African swine fever vaccine strain; after the attenuated African swine fever vaccine strain immunizes pigs, the pigs are completely attenuated, the immunized pigs are healthy, high-level protective antibodies are detected in the blood of the immunized pigs, and 100% immune protection can be provided to the ASFV CN / GS / 2018 virulent strain attack, so that the attenuated African swine fever vaccine strain can be used as a safe and effective African swine fever candidate vaccine and has great social value.

The application is suitable for the fields of genetic engineering and biological medicine technology, and provides a fusion recombinant protein ABT for preventing brucellosis and application of the fusion recombinant protein ABT in preparation of a protective vaccine. The fusion recombinant protein ABT is composed of an immune enhancement antigen and a multi-epitope tandem antigen. The immune enhancement antigen (named as A) comprises a Brucella ribosome L7 / L12 protein and a PADRE sequence. The multi-epitope tandem antigen is composed of a dominant B cell epitope part (named as B) derived from Brucella SurA, OMP31, BP26 and Trigger factor protein and a dominant Tc cell epitope and Th cell epitope part (named as T) in series. The ABT Brucella multi-epitope subunit vaccine prepared by mixing the fusion recombinant protein ABT and an immune adjuvant has the characteristics of good purity, high safety and strong immunogenicity, can stimulate the body to produce protective antibodies, and the antibodies can be maintained for a long time.

The invention relates to an emulsion with long-acting immune response and a preparation method and application thereof, the emulsion comprises a water phase, an oil phase and particles, the water phase comprises an inner water phase and an outer water phase, the inner water phase contains the particles, the oil phase wraps the inner water phase, and the outer water phase wraps the oil phase. According to the emulsion provided by the invention, the particles are introduced into the emulsion, the deformability of the emulsion and the bionic characteristics of the particles are utilized, cellular uptake and efficient lymph node enrichment are remarkably enhanced, rapid and powerful hair growth center reaction is induced, a body can be induced to generate strong cellular and humoral immune response on a mouse model, and a protective antibody is continuously generated.

The invention belongs to the technical field of cellular immunity, and particularly relates to a DC-CIK cell culture method based on an HBV protective antibody positive healthy donor and application, the cell culture method comprises the following steps: selecting HBsAg negative and anti-HBs antibody positive healthy donor peripheral blood mononuclear cells, loading a dendritic cell (DC) by using a mixed antigen of HBcAg and HBsAg, and culturing the DC-CIK cell by using a cell culture medium. And co-culturing the DC cells and cytokine-induced killer cells (CIK) to finally obtain the allogenic DC-CIK cells. According to the invention, DC cells of healthy donors and CIK cells are co-cultured to obtain allogenic DC-CIK cells, an HBcAg and HBsAg mixed antigen loading technology is adopted to significantly improve the antigen presentation capability of the DC cells, an optimized culture system enhances the targeting killing function of the cells, and the HBsAg clearance rate and the cccDNA inhibition rate can be effectively improved in combination with nucleoside analogue treatment, so that the DC-CIK cells can be used for preparing the DC-CIK cells. The synergistic breakthrough of efficient virus removal, immune function reconstruction and low recurrence rate in hepatitis B treatment is realized.

The invention provides an immune injection method of a rabies vaccine for Mongolia cattle, which adopts a dog rabies inactivated vaccine to immunize the Mongolia cattle, and comprises the following steps: injecting 2ml of rabies inactivated vaccine for each Mongolia cattle, and injecting for the second time after 17-21 days. Test results show that the Mongolia cattle can generate protective antibodies 17 days after first injection, the antibody titer mean value reaches a peak value 115 days after second injection, and the immune protection period can last for at least 12 months. The invention also provides an alternative scheme of one-time 5ml injection, and also has a good immune effect. The method can effectively prevent rabies of Mongolian cattle, is suitable for a desert steppe grazing environment, and has popularization and application values.

The present disclosure provides a GLP1 analogue and a GLP1 / GIP receptor co-agonist analogue, a fusion protein comprising the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, and methods of use thereof. In various embodiments, the fusion protein comprises the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, which is fused to a protective antibody, or further fused to a stabilizing domain. In one embodiment, the fusion protein can be used to treat or ameliorate symptoms or indications of diseases such as obesity and diabetes.

The present invention discloses a genotype VII Newcastle disease attenuated marker vaccine strain rMG7-F-N471A, which has a deposit number of CGMCC No.46293. The full gene nucleotide sequence of the vaccine strain is shown in SEQ ID No: 1; wherein, the 471st amino acid asparagine (N) of the F protein is replaced by alanine (A). The present invention utilizes a Newcastle disease virus reverse genetic operation platform, and on the basis of the Newcastle disease virus MG7 strain, mutates different sites to rescue a genotype VII Newcastle disease virus marker vaccine attenuated strain rMG7-F-N471A with low pathogenicity, good growth characteristics, high virus titer, stable passage, and excellent immunogenicity. The marker vaccine strain has good immunogenicity, can induce a high level of protective antibodies, and achieves complete protection for immunized chickens. It can be used to prevent and control the currently prevalent genotype VII Newcastle disease virus and lay the foundation for distinguishing vaccine immunity from wild virus infection.

The present invention relates to the development of an engineered polypeptide complex, aimed at inducing protective antibody responses against the Monkey pox virus. The polypeptide complex is structured with antigenic domains connected via specific linkers to a nanocage vehicle. When expressed in a suitable bacterial expression system, the complex generates a recombinant soluble protein that, upon administration in vivo, elicits an immune response that provides protection against Mpox virus infection. The invention also covers the method for producing this engineered polypeptide complex, as well as a vaccine formulation comprising the complex along with pharmaceutically acceptable excipients.

Provided are a polynucleotide encoding a chimeric or mixed antigen of poxvirus multiple immunogens, a related nucleic acid product thereof, and the use thereof in the preparation of a vaccine for preventing and / or treating poxvirus (in particular monkeypox virus) infection. The chimeric or mixed antigen of the poxvirus multiple immunogens encoded by the polynucleotide comprises two immunogens: a monkeypox virus A35R protein or an antigenic fragment thereof (or an appropriate variant thereof) and a monkeypox virus MIR protein or an antigenic fragment thereof (or an appropriate variant thereof). The immunogen components of the chimeric or mixed nucleic acid vaccine based on the polynucleotide are clear, and the chimeric or mixed nucleic acid vaccine can efficiently stimulate specific immune responses (for example, generating a protective antibody) against poxvirus (in particular monkeypox virus), can be used for preventing and / or treating poxvirus (in particular monkeypox virus), and has high clinical application prospects.

The invention provides a Marburg GP protein mutant, a DNA molecule, a recombinant vector and application thereof, and belongs to the technical field of Marburg virus vaccine preparation, the Marburg GP protein mutant is obtained by site mutation on the basis of wild type Marburg GP protein, and comprises at least one mutation selected from R575P, V576P and L585P; the amino acid sequence of the wild Marburg GP protein is as shown in SEQ ID NO: 1. The Marburg GP mutant can provide stable GP pre-fusion conformation, can induce mice to generate higher binding activity, neutralizing activity and protective antibodies, and is expected to be used for preparing Marburg virus vaccines.

The application discloses a Haemonchus contortus antigen protein combination and application thereof in preparation of a Haemonchus contortus immunoprotective subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises galactose and fucose modified antigen proteins MEP1, MEP3, MEP4, PEP2 and CP1, the fucose modification comprises proximal and distal alpha 1,3 fucose modification, the antigen proteins in the subunit vaccine are closer to natural proteins in terms of N glycosylation modification, the subunit vaccine can induce goats to generate protective antibodies after mixed immunization, and can significantly reduce the parasitic quantity of Haemonchus contortus in the goats and the oviposition quantity of the worms. The subunit vaccine can be used for preparing a drug for preventing and treating Haemonchus contortus disease. The application lays a foundation for development of a Haemonchus contortus subunit vaccine, provides an effective technical means for prevention and treatment of the disease, and has important application value and popularization prospect.

Developing an effective HIV-1 vaccineis contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, vaccine candidates such as LC3.SOSIP(w) and LC3.SOSIP(s) showed promising results in New Zealand white rabbits. These candidates elicited significantly higher Env-specific IgG levels than controls, demonstrated high affinity for SOSIP antigens in ELISA binding assays, and achieved broad neutralizing capabilities against multiple HIV-1 pseudoviruses in TZM-bl neutralization assays. In conclusion, HIV Env antigen can be adaptively targeted to LC as a trimer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such constructs as LC targeting HIV-1 vaccines.

This invention discloses a Newcastle disease virus (NDV) genotype VII attenuated marker vaccine strain, rMG7-HN-G256E, with accession number CGMCC No. 46292. The complete nucleotide sequence of this vaccine strain is shown in SEQ ID No: 1; wherein, the 256th amino acid (G) of the HN protein is replaced with glutamic acid (E). This invention utilizes a Newcastle disease virus reverse genetics platform to mutate different sites on the MG7 Newcastle disease virus strain, rescuing a genotype VII Newcastle disease virus marker vaccine strain, rMG7-HN-G256E, which exhibits low pathogenicity, good growth characteristics, high viral titer, stable passage, and excellent immunogenicity. This marker vaccine strain has good immunogenicity, can induce high levels of protective antibodies, and provides complete protection for immunized chickens. It can be used to control the currently prevalent genotype VII Newcastle disease virus and lays the foundation for differentiating between vaccine immunization and wild-type virus infection.